The first results with MV130 in COPD patients have been presented at the European Respiratory Society (ERS) congress, showing its efficacy in reducing the number and intensity of exacerbations associated with this disease. The phase 3 study has been conducted in 7 hospitals including 198 patients that were followed during 18 months.

Alergia ocupacional al polen de melocotonero

According to a study published in PLOS One, allergic patients with respiratory symptoms to peach tree pollen through their sensitization by Pru p 9 can tolerate the consumption of this fruit even if they are sensitized by Pru p 3, the main peach fruit allergen. This study, coordinated by Dr. Miguel Blanca, has been performed with the contribution of INMUNOTEK.


AJRCCM publishes in its August issue the results of the efficacy of MV130 in the prevention of recurrent wheezing attacks in young children. This is a randomized, double-blind, placebo-controlled phase 3 clinical trial conducted in two hospitals in Spain. The results are highlighted in an Editorial, which points out its importance as a new therapeutic option for the prevention of these processes and the implication of innate immune training as a possible mechanism of action.

MV130 (Bactek)

MV130 (Bactek) prevents recurrent respiratory infections in patients with common variable immunodeficiency (CVID) according to a pilot study published in Biomedicines. The study is a proof of concept to evaluate MV130 as a trained immunity-based vaccine (TIbV) in CVID patients with recurrent respiratory infections despite prophylactic treatment with replacement immunoglobulins and antibiotics.

The research study on the effect of aluminum in the new allergoid-mannan conjugates carried out at the Complutense University of Madrid and INMUNOTEK published in Allergy, has been selected to be included in the opening issue of the Virtual Issue collection, aimed to promote the dissemination of outstanding studies.

Financial Times

Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.

Inmunotek Pyme del año 2019

INMUNOTEK has been awarded as the Best SME of the Year 2019 by CEPYME (Spanish Confederation of Small and Medium-Sized Enterprises). This award recognizes Business Excellence under the criteria of business activity, innovation, internationalization and job creation. The award ceremony was chaired by the Spanish Minister of Economy and Business, Nadia Calviño, the President of CEPYME, Gerardo Cuerva and the CEO of Santander Bank, Rami Aboukhair, as sponsor of the award.

The effect of aluminum hydroxide on the tolerogenic properties of dendritic cells induced by allergoids coupled to mannan has been published in Allergy with the title “Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs”. The study has been carried out at the School of Chemistry of the Complutense University of Madrid with the collaboration of INMUNOTEK.

Cursos verano El Escorial

Within the Summer Courses of El Escorial organized by the Complutense University of Madrid, the one entitled “Trained immunity-based vaccines: the innate immune memory working towards  antiinfectious immunotherapy” was held in Madrid during 11-12th of July under the direction of Dr. Silvia Sánchez Ramón (Immunology, San Carlos Clinical Hospital, Madrid) and Dr. Laura Conejero Hall (INMUNOTEK), Scientific Secretariat. The course, sponsored by INMUNOTEK, has combined basic aspects of the mechanisms of action of trained immunity, with the clinical outcome in recurrent respiratory and urinary tract infections.

Allergy to mosquitoes and mites is common in certain geographic areas and both have important allergens such as tropomyosin that can lead to cross-reactions between them. A study has been published in Clinical Experimental Allergy which shows that the mosquito Aedes aegypti and the mite Dermatophagoides pteronyssinus share regions in their tropomyosin that justify the cross-response of antibodies and T cells.